Terms: = Prostate cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
70 results:
1. Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi P; Freeman D; Thomas J; Ravi A; Mantia C; McGregor BA; Berchuck JE; Epstein I; Budde P; Ahangarian Abhari B; Rupieper E; Gajewski J; Schubert AS; Kilian AL; Bräutigam M; Zucht HD; Sonpavde G
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309723
[TBL] [Abstract] [Full Text] [Related]
2. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.
Yuan T; Zhang S; He S; Ma Y; Chen J; Gu J
Sci Rep; 2023 Sep; 13(1):15916. PubMed ID: 37741901
[TBL] [Abstract] [Full Text] [Related]
3. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
4. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
5. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract] [Full Text] [Related]
6. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
7. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical prostate cancer treatment: A Pan prostate cancer Group Study.
Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
[TBL] [Abstract] [Full Text] [Related]
8. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
Masuda T; Kosaka T; Nakamura K; Hongo H; Yuge K; Nishihara H; Oya M
BMC Med Genomics; 2022 May; 15(1):118. PubMed ID: 35598018
[TBL] [Abstract] [Full Text] [Related]
9. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
Arriaga JM; Panja S; Alshalalfa M; Zhao J; Zou M; Giacobbe A; Madubata CJ; Kim JY; Rodriguez A; Coleman I; Virk RK; Hibshoosh H; Ertunc O; Ozbek B; Fountain J; Jeffrey Karnes R; Luo J; Antonarakis ES; Nelson PS; Feng FY; Rubin MA; De Marzo AM; Rabadan R; Sims PA; Mitrofanova A; Abate-Shen C
Nat Cancer; 2020 Nov; 1(11):1082-1096. PubMed ID: 34085047
[TBL] [Abstract] [Full Text] [Related]
10. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal cancer.
Rajamäki K; Taira A; Katainen R; Välimäki N; Kuosmanen A; Plaketti RM; Seppälä TT; Ahtiainen M; Wirta EV; Vartiainen E; Sulo P; Ravantti J; Lehtipuro S; Granberg KJ; Nykter M; Tanskanen T; Ristimäki A; Koskensalo S; Renkonen-Sinisalo L; Lepistö A; Böhm J; Taipale J; Mecklin JP; Aavikko M; Palin K; Aaltonen LA
Gastroenterology; 2021 Aug; 161(2):592-607. PubMed ID: 33930428
[TBL] [Abstract] [Full Text] [Related]
11. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
12. Synthesis of Silica Based Nanoparticles Against the Proliferation of Human prostate cancer.
Durmus IM; Deveci I; Karakurt S
Anticancer Agents Med Chem; 2021; 21(18):2553-2562. PubMed ID: 33557739
[TBL] [Abstract] [Full Text] [Related]
13. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract] [Full Text] [Related]
14. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients.
Zhang Y; Yao Y; Xu Y; Li L; Gong Y; Zhang K; Zhang M; Guan Y; Chang L; Xia X; Li L; Jia S; Zeng Q
Nat Commun; 2021 Jan; 12(1):11. PubMed ID: 33397889
[TBL] [Abstract] [Full Text] [Related]
15. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Toomey S; Carr A; Mezynski MJ; Elamin Y; Rafee S; Cremona M; Morgan C; Madden S; Abdul-Jalil KI; Gately K; Farrelly A; Kay EW; Kennedy S; O'Byrne K; Grogan L; Breathnach O; Morris PG; Eustace AJ; Fay J; Cummins R; O'Grady A; Kalachand R; O'Donovan N; Kelleher F; O'Reilly A; Doherty M; Crown J; Hennessy BT
J Transl Med; 2020 Feb; 18(1):99. PubMed ID: 32087721
[TBL] [Abstract] [Full Text] [Related]
16. Single Lesion on prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent prostate cancer.
Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
[TBL] [Abstract] [Full Text] [Related]
17. Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine.
Sueoka E; Watanabe T; Mashima T; Shirakami Y; Komori A; Matsuo K; Yoshikawa HY; Cho KA; Park TJ; Seimiya H; Kim EG; Suganuma M; Chung J
J Cancer Res Clin Oncol; 2019 May; 145(5):1263-1271. PubMed ID: 30859317
[TBL] [Abstract] [Full Text] [Related]
18. Liquid Biopsy to Identify Actionable Genomic Alterations.
Ou SI; Nagasaka M; Zhu VW
Am Soc Clin Oncol Educ Book; 2018 May; 38():978-997. PubMed ID: 30231331
[TBL] [Abstract] [Full Text] [Related]
19. Cotargeting the Cell-Intrinsic and Microenvironment Pathways of prostate cancer by PI3Kα/β/δ Inhibitor BAY1082439.
Zou Y; Qi Z; Guo W; Zhang L; Ruscetti M; Shenoy T; Liu N; Wu H
Mol Cancer Ther; 2018 Oct; 17(10):2091-2099. PubMed ID: 30045927
[TBL] [Abstract] [Full Text] [Related]
20. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract] [Full Text] [Related]
[Next]
